Lupus Market Synopsis and Highlights, Key Findings, Major Companies Analysis and Forecast to 2023

Market Highlights:

The Global Lupus Market is anticipated to have held a market value of USD 1.48 billion in the year 2017 and is expected to grow at a CAGR of 11.2% during the forecast period.

Lupus is an autoimmune disease in which the immune system produces antibodies that attack the body’s healthy tissue. The antibodies produced by the immune system in lupus cause inflammation, tissue damage, and pain. Majority of the patients affected by lupus are women, and the majority of the people develop lupus between 15 to 45 years of age. The growing prevalence of lupus, ongoing medical advancements in the treatment of systemic lupus erythematosus, rising research and development activities are some factors that are expected to propel the market growth during the assessment period. On the other hand, the factors such as strict government regulation and increasing prices of lupus drugs may hinder the market growth over the assessment period.

Many companies are engaged in the global lupus market. The prominent players in the market are engaged in strategic collaborations, and new product launches to strengthen their market position. For instance, in January 2017, Sanofi and ImmuNext agreed to develop treatments for autoimmune diseases including multiple sclerosis and lupus.

Get Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/6636

Key Players:

Some of the prominent players in the global lupus market are Aurinia Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Cadila Healthcare, GlaxoSmithKline plc, Mylan N.V., F. Hoffmann-La Roche AG, Pfizer, Inc., Sanofi, Lycera Corporation, Eli Lily and Company, and Merck KGaA.

Segmentation:

The Global Lupus Market has been segmented into type, treatment, and end user. The global market, by types, has been segmented into systemic lupus erythematosus, cutaneous lupus erythematosus, drug-induced lupus erythematosus, and neonatal lupus. The systemic lupus erythematosus segment is expected to hold the largest market share owing to the growing prevalence and increasing drug development in recent years.

On the basis of treatment, the global market has been segmented into nonsteroidal anti-inflammatory drugs (NSAIDs), antimalarial drugs, corticosteroids, immunosuppressants, biologics, and other.

On the basis of end user, the global market has been segmented into hospital & clinics, diagnostic laboratories, and others.

Access Report Details @ https://www.marketresearchfuture.com/reports/lupus-market-6636

Regional Analysis:

Geographically, the Americas is expected to dominate the global market owing to the presence of well-developed healthcare sector, rising demand for better treatment options, growing prevalence of lupus, government initiatives for lupus, and availability of reimbursement. Europe is expected to hold the second largest position in the global lupus market owing to the increasing number of research and development activities and the rising prevalence of lupus in the region. Asia-Pacific region is anticipated to be the fastest growing region owing to the growing prevalence of lupus, continuously growing healthcare sector and increasing regional expansion by prominent market players. The Middle East & Africa has the lowest share of the market. Majority of the market of this region is expected to be held by the Middle East region due to a well-developed healthcare sector.

Ashu Kalbande Senior Web Marketing Executive at WiseGuy Research Future